Clinical Trials Browser

Phase 2 × Breast Neoplasms × tocilizumab × Clear all

NCT05846789 2026-05-08

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04871854 2022-11-01

Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints

Phase 2 Completed

Breast Neoplasms